These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 721948)

  • 1. Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals.
    Ishizaki T; Tawara K; Oyama Y; Nakaya H
    J Clin Pharmacol; 1978; 18(11-12):511-8. PubMed ID: 721948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of disposition and effect of timolol and propranolol on exercise tachycardia.
    Ishizaki T; Tawara K
    Eur J Clin Pharmacol; 1978 Nov; 14(1):7-14. PubMed ID: 32043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade.
    Wilson TW; Firor WB; Johnson GE; Holmes GI; Tsianco MC; Huber PB; Davies RO
    Clin Pharmacol Ther; 1982 Dec; 32(6):676-85. PubMed ID: 7140133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships among timolol doses, plasma concentrations and beta-adrenoceptor blocking activity.
    Ferguson RK; Vlasses PH; Koplin JR; Holmes GI; Huber P; Demetriades J; Abrams WB
    Br J Clin Pharmacol; 1982 Nov; 14(5):719-25. PubMed ID: 6128021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma timolol levels and systolic time intervals.
    Singh BN; Williams FM; Whitlock RM; Collett J; Chew C
    Clin Pharmacol Ther; 1980 Aug; 28(2):159-66. PubMed ID: 7398183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic differences between single and multiple oral dosing with the guidance for beta-adrenoceptor blockade assessment.
    Ishizaki T; Tawara K
    Cardiology; 1979; 64 Suppl 1():25-43. PubMed ID: 42487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics and kinetics of ophthalmic timolol.
    Affrime MB; Lowenthal DT; Tobert JA; Shirk J; Eidelson B; Cook T; Onesti G
    Clin Pharmacol Ther; 1980 Apr; 27(4):471-7. PubMed ID: 7357805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacologic observations on timolol. II. Antihypertensive effect and kinetic disposition on twice-daily dosing in patients with mild or moderate hypertension.
    Ishizaki T; Tawara K; Oyama Y; Nakaya H
    J Clin Pharmacol; 1978; 18(11-12):519-29. PubMed ID: 721949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timolol kinetics in chronic renal insufficiency.
    Lowenthal DT; Pitone JM; Affrime MB; Shirk J; Busby P; Kim KE; Nancarrow J; Swartz CD; Onesti G
    Clin Pharmacol Ther; 1978 May; 23(5):606-15. PubMed ID: 639436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin.
    McGourty JC; Silas JH; Fleming JJ; McBurney A; Ward JW
    Clin Pharmacol Ther; 1985 Oct; 38(4):409-13. PubMed ID: 2864157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers.
    Mäntylä R; Männistö P; Nykänen S; Koponen A; Lamminsivu U
    Eur J Clin Pharmacol; 1983; 24(2):227-30. PubMed ID: 6840172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days.
    McCrea JB; Vlasses PH; Franz TJ; Zeoli L
    Pharmacotherapy; 1990; 10(4):289-93. PubMed ID: 2388875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oral timolol studied by mass fragmentography.
    Fourtillan JB; Courtois P; Lefebvre MA; Girault J
    Eur J Clin Pharmacol; 1981 Feb; 19(3):193-6. PubMed ID: 7215417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption of ocular timolol.
    Alvan G; Calissendorff B; Seideman P; Widmark K; Widmark G
    Clin Pharmacokinet; 1980; 5(1):95-100. PubMed ID: 7363532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the systemic bioavailability of timolol in man.
    El-Rashidy R
    Biopharm Drug Dispos; 1981; 2(2):197-202. PubMed ID: 7248483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ophthalmic administration of S-596 (Arotinolol) on intraocular pressure and haemodynamics in health volunteers: comparison with timolol.
    Nakashima M; Uematsu T; Takiguchi Y; Hashimoto H; Watanabe I; Morioka S; Hibino T
    Eur J Clin Pharmacol; 1985; 28(4):391-6. PubMed ID: 2411566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous timolol in patients with acute myocardial infarction and in healthy volunteers.
    Vedin JA; Kristianson JK; Wilhelmsson CE
    Eur J Clin Pharmacol; 1982; 23(1):43-7. PubMed ID: 7128671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects.
    Ferro A; Hall JA; Dickerson JE; Brown MJ
    Br J Clin Pharmacol; 1997 Mar; 43(3):301-8. PubMed ID: 9088585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active transport of beta-adrenergic blocking agents in the anterior uvea of albino rabbit.
    Matsumoto S; Araie M; Takase M
    Jpn J Ophthalmol; 1986; 30(4):339-50. PubMed ID: 2884338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.
    Wellstein A; Palm D; Pitschner HF; Belz GG
    Eur J Clin Pharmacol; 1985; 29(2):131-47. PubMed ID: 3000793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.